Becton Dickinson to Split from Bioscience and Diagnostic Solutions Arms
American medical technology (MedTech) company Becton Dickinson (BDX) plans to split from its bioscience and diagnostic solutions arms to become
Becton Dickinson Q1 Earnings: Revenue And EPS Beat, Lowers Outlook, Outlines Intent To Separate Biosciences And Diagnostic Solutions Business
Becton, Dickinson and Company (NYSE:BDX) authorized to pursue a plan to separate BD’s Biosciences and Diagnostic Solutions business from the rest of BD to enhance strategic focus, and growth-oriented investments and capital allocation.
Becton Dickinson to break off biosciences, diagnostic solutions
Becton Dickinson said it would focus on medtech and prioritize research, acquisitions and high-growth markets.
Becton Dickinson to Separate From Bioscience and Diagnostic Solutions Business
Chief Executive Tom Polen said he believes the separation would help differentiate BD in the medical-technology industry, and allow the company to invest more in innovation and margin growth.
Becton Dickinson outlines $14.30-$14.60 EPS target for FY25 amid planned biosciences separation
Q1 2025 Management View Tom Polen emphasized several key updates, including the planned separation of BD’s Biosciences and Diagnostic Solutions businesses, which aims to create two strategically aligned entities.
Becton looks to separate biosciences and diagnostic solutions after upbeat quarterly results
Becton Dickinson beat expectations for first-quarter results and said its board has authorized a plan to separate its biosciences and diagnostic solutions unit on Wednesday, as the medical device maker aims to focus on its core business.
Becton Dickinson & Co. stock underperforms Thursday when compared to competitors
Becton Dickinson & Co. closed 9.83% short of its 52-week high of $251.99, which the company reached on February 3rd.
Becton Dickinson looks to divest life sciences unit at $30 billion valuation, source says
U.S. medical device maker Becton Dickinson is considering a potential separation of its life sciences unit at a valuation of ...
Becton to Pare Part of Life Sciences Unit to Boost Stock (1)
Becton Dickinson & Co. said it’s planning to separate part of its life sciences segment in a move aimed at raising the medical technology company’s stock.
Becton Dickinson & Co. stock outperforms competitors on strong trading day
Becton Dickinson & Co. closed 2.75% below its 52-week high of $251.99, which the company reached on February 3rd.
Becton Dickinson gains amid reports it's evaluating separating life sciences unit
Becton Dickinson (BDX) rose 2.4% in premarket trading as reports surface of potential separation of its $30 billion life ...
Becton Dickinson to Separate Biosciences and Diagnostic Solutions Business
BD plans to separate its Biosciences and Diagnostic Solutions unit into an independent company by fiscal 2026.